Products with Immunomodulators bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN4619 | Rhamnocitrin |
| 1. Rhamnocitrin and kaempferol can augment cellular antioxidant defense capacity, at least in part, through regulation of HO-1 expression and MAPK signal transduction. 2. Rhamnocitrin and kaempferol not only protect low-density lipoprotein from oxidation but also prevent atherogenesis through suppressing macrophage uptake of oxidized low-density lipoprotein. 3. Rhamnocitrin can enhance the immune function, improve the formation of spleen cells of mice serum hemolysin of chicken red blood cell immune. 4. Rhamnocitrin shows a significant protection against cloudiness in lenses induced by hydrogen peroxide and hydrocortisone in a dose dependent manner, suggests that rhamnocitrin possesses significant anticataract activity and acts most likely due to its antioxidant property. | |
| BCN4686 | Hautriwaic acid |
| 1. Hautriwaic acid diminishes the joint edema induced by this mixture of polysaccharides (carrageenan), possibly by acting as immunomodulator of the inflammatory response. 2. Hautriwaic acid present in the methanolic extract and its ethyl acetate, and aqueous fractions may be responsible for this hepatoprotective activity of Dodonaea viscosa which was confirmed by in vivo experiments. 3. Hautriwaic acid shows anti-inflammatory activity in 12-O-tetradecanoylphorbol 13-acetate (TPA) mice ear edema models. | |
| BCN4896 | Parthenolide |
| Parthenolide exhibits anti-cancer, anti-inflammatory, immunomodulatory, anti-Leishmania, and antimigraine effects, it inhibits nociception and neurogenic vasodilatation in the trigeminovascular system by targeting the TRPA1 channel.Parthenolide is also an inhibitor of the nuclear factor-kappaB pathway, can ameliorate cardiovascular derangement and outcome in endotoxic shock in rodents. | |
| BCN5010 | Esculentoside A |
| Esculentoside A has anti-inflammatory activity , can suppress inflammatory responses in LPS-induced ALI through inhibition of the nuclear factor kappa B and mitogen activated protein kinase signaling pathways. Esculentoside A may be useful for the treatment of autoimmune disease through modulation on T cell-mediated adaptive immunity. Esculentoside A treatment can attenuate CCl4 and GalN/LPS-induced acute liver injury in mice. | |
| BCN5020 | Vitexicarpin |
| Vitexicarpin has shown antitumor, cytotoxicity, anti-inflammatory, analgesic and immunoregulatory properties.Vitexicarpin can act as a novel angiogenesis inhibitor, it exerts good antiangiogenic effects by inhibiting vascular-endothelial-growth-factor-(VEGF-) induced endothelial cell proliferation, migration, and capillary-like tube formation on matrigel in a dose-dependent manner. It can significantly reduce vascular inflammation, through inhibition of ROS-NF-κB pathway in vascular endothelial cells. | |
